tinued to make significant progress on our strategic evolution.As a result,in a macro environment where equity issuance hit a nearly two-decade low,we performed better than we would have three years ago.In the pages that follow,we lay out in detail the state of our franchise as well as ...
Ltd., Class A (Materials) 1,500 Yunnan Tin Co. Ltd., Class A (Materials) 1,700 Yunnan Yuntianhua Co. Ltd., Class A (Materials) 1,374 Zai Lab Ltd., 02/28/23 ADR (Health Care)* 1,500 Zangge Mining Co. Ltd., Class A (Materials) 600 Zhangzhou Pientzehuang Pharmaceutical Co. ...
Ltd., Class A (Materials) 405 Yunnan Tin Co. Ltd., Class A (Materials) 405 Yunnan Yuntianhua Co. Ltd., Class A (Materials) 333 Zai Lab Ltd. ADR (Health Care)* 324 Zangge Mining Co. Ltd., Class A (Materials) 105 Zhangzhou Pientzehuang Pharmaceutical Co. Ltd., Class A (Health ...
International Journal of Molecular Sciences Article Investigating Immune Responses to the scAAV9-HEXM Gene Therapy Treatment in Tay–Sachs Disease and Sandhoff Disease Mouse Models Shalini Kot 1,† , Subha Karumuthil-Melethil 2,†, Evan Woodley 1, Violeta Zaric 2,3, Patrick Thompson 4, ...